BioMed Research International / 2015 / Article / Tab 4

Research Article

Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis

Table 4

Clinical and molecular characteristics of the different clusters.

AttributeCluster 1Cluster 2Cluster 3Cluster 4

Age*61 years; 1867 years; 970 years; 982 years; 9
(23–73)(52–79)(60–82)(72–93)

MultiplicityNo: 100%No: 20%No: 40%No: 50%
Yes 0%Yes 80%Yes 60%Yes 50%

TM > 3 cmNo: 71%No: 50%No: 60%No: 0%
Yes: 29%Yes: 50%Yes: 40%Yes: 100%

GradeG1: 83.3%G1: 0%G1: 20%G1: 0%
G2: 16.6%G2: 62.5%G2: 80%G2: 50%
G3: 0%G3: 37.5%G3: 0%G3: 50%

TNMTa: 100%Ta: 0%Ta: 80%Ta: 0%
T1: 0%T1: 100%T1: 20%T1: 100%

Risk group [26] Low-Int: 100%Low-Int: 0%Low-Int: 80%Low-Int: 0%
High: 0%High: 100%High: 20%High: 100%

Risk group [38] Low-Int: 100%Low-Int: 12.5%Low-Int: 100%Low-Int: 0%
High: 0%High: 87.5%High: 20%High: 100%

p53 (ng/mL)*0.1; 0.20.5; 1.20; 00; 0
(0–0.6)(0–3.40)(0-0)(0-0)

neu (HNU/mL)*748.5; 415.6775.4; 544.21379.9; 184.7854.4; 497.7
(328–1596.1)(76–1749.1)(1253.0–1698.1)(330.9–1527.2)

EGRF (fmol/mg)*6.9; 4.012.5; 12.88.5; 4.722.8; 17.2
(0.2–11.4)(2.2–16.6)(3.0–15.1)(7.1–39.5)

GS (months)*104; 37 (47–128)93; 46 (3–135)84; 47 (23–133)17; 10 (5–28)

RFS (months)*104; 37 (47–128)81; 56 (3–135)9; 4 (4–13)13; 10 (5–27)

PFS (months)*104; 37 (47–128)93; 46 (3–135)84; 47 (23–133)13; 10 (5–27)

Mean; SD (range).

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.